DJIA 17,835.89 25.83 0.15%
NASDAQ 4,737.74 24.77 0.53%
S&P 500 2,068.92 5.42 0.26%
market minute promo

GlaxoSmithKline (NYSE: GSK)



company name or ticker
Company Photos
(Click to zoom)

Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October

ISIS Pharmaceuticals was among October's top performing biotech stocks. Find out why ISIS catapulted higher by 19%, as well as whether or not this run can continue.

GlaxoSmithKline PLC (GSK) Ex-Dividend Date Scheduled for November 05, 2014

Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog

Arena Pharmaceuticals, Inc. Earnings: Looking for More

A prescription growth rate of 30% sounds good, but Belviq has such low sales, it's hard to get too excited yet. If phase 3 trials pan out, long-term growth will likely come from use as a smoking cessation drug and as a combination product for obesity.

Ebola play Halyard Health stock gains are modest

7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides

Update: GSK Starts Promoting Theravance Drugs More Actively

GlaxoSmithKline: Why I Bought Shares Of This High-Yield Health Care Stock

Seattle Genetics, Inc. Posts Record Adcetris Sales

A solid quarter for the biotech allowed it to raise guidance for the year.

United Therapeutics Sells Off On Good News - Why I Bought That Dip

See More Articles...